Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 13/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478365 | 1.00 | CTSA (0.47) | CTSAMEN1KMT2AACP3CASP1 | |
| SCHEMBL25253132 | 1.00 | CTSA (0.47) | CTSAMEN1KMT2AACP3CASP1 | |
| SCHEMBL5720969 | 1.00 | CTSA (0.47) | CTSAMEN1KMT2AACP3CASP1 | |
| SCHEMBL381519 | 0.86 | KMT2A (0.51) | CTSAMEN1KMT2A | |
| SCHEMBL31701959 | 0.86 | KMT2A (0.51) | CTSAMEN1KMT2A | |
| SCHEMBL5720933 | 0.86 | KMT2A (0.51) | CTSAMEN1KMT2A | |
| SCHEMBL19808782 | 0.84 | CASP1 (0.44) | CTSAMEN1KMT2ACASP1 | |
| SCHEMBL12494460 | 0.83 | CFD (0.54) | CTSAMEN1KMT2A | |
| SCHEMBL811540 | 0.82 | CYP2D6 (0.42) | ACP3 | |
| Hydrochloric Acid SCHEMBL2778473 | 0.81 | CYP2D6 (0.41) | CTSAACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4230387-A | — | — | None | — | — | JP | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | BIONDI RICARDO M | 2007-02-08 | — | — | US | disclosed |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-10-19 | — | — | US | disclosed |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | UBE INDUSTRIES, LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| WO-2006069799-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS B.V. (NL) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1621529-A1 | 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO | Ube Industries, Ltd. (JP) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
| JP-H04230387-A | PRODUCTION OF N-PHENYLACETIC ACID DERIVATIVE OF THETRAHYDROTHIENO(3,2-C)PYRIDINE AND ITS INTERMEDIATE | SANOFI SA | 1992-08-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | CTSA 2973/4885MEN1 2181/4885KMT2A 384/4885 |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, LIPG | CTSA 1242/4885MEN1 2447/4885KMT2A 3961/4885 |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | CTSA 2643/4885MEN1 287/4885KMT2A 2844/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | CTSA 3353/4885MEN1 383/4885KMT2A 718/4885 |
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | CTSA 1004/4885MEN1 824/4885KMT2A 1262/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | CTSA 2890/4885MEN1 178/4885KMT2A 3224/4885 |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | ALAD, ARSA, ALDH7A1 | CTSA 742/4885MEN1 4143/4885KMT2A 4127/4885 |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | CYP7A1, UGT1A1, CYP2F1 | CTSA 2845/4885MEN1 85/4885KMT2A 4178/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | CTSA 3757/4885MEN1 3790/4885KMT2A 2227/4885 |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, MCL1 | CTSA 1116/4885MEN1 2560/4885KMT2A 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.